Personalis reports $33.8 million net loss for Q3 2026

Exhibits

Signatures

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "will," or "would" or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following:

• the planned completion of the transactions contemplated by the Agreement and Plan of Merger by and among us, Tempus AI, Inc. ("Tempus"), Aviary Development, Inc., a Delaware corporation and a wholly owned subsidiary of Tempus and Toucan Development, LLC, a Nevada limited liability company and a wholly owned subsidiary of Tempus;

• the evolution of cancer therapies and market adoption of our testing services;

• estimates of our future revenue and the timing thereof, expenses, use of cash and other resources, cost savings, capital requirements, and our needs for additional financing and our ability to obtain financing when needed;

• future reimbursement and reimbursement rulings and the timing thereof;

• our business strategies, including our aim to focus on certain indications and the timing thereof;

• the benefits of our testing services, including their ability to increase the probability of clinical trial success;

• our ability to enter into and compete effectively in existing and new markets, with existing competitors and new market entrants;

• our ability to manage and grow our business by expanding our sales to existing customers or introducing our testing services to new customers;

• our sales, marketing and commercialization plans and strategies, including the expected benefits of and activities to be performed under our Commercialization and Reference Laboratory Agreement with Tempus;

• our future business with the U.S. Department of Veterans Affairs' Million Veteran Program ("VA MVP"), ModernaTX, Inc. ("Moderna"), Merck & Co., Inc. ("Merck"), and other collaboration partners and customers;

• our belief that approval of personalized cancer therapies by the U.S. Food and Drug Administration ("FDA") may drive benefits to our business;

• our ability to benefit from the scaling of our infrastructure and capacity at our headquarters facility in Fremont;

• the impact our collaboration agreements and key opinion leaders may have on the broader use of our testing services in the future;

• the potential impacts of inflation, macroeconomic conditions, and geopolitical conflicts on our business and operations;

• our ability to establish and maintain intellectual property protection for our testing services or avoid claims of infringement;

• our success in defending and enforcing our intellectual property rights, including patents;

• potential effects of government regulation;

• our ability to hire and retain key personnel; and

• our ability to maintain proper and effective internal controls.

Actual events or results may differ from those expressed in forward-looking statements. As such, you should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, operating results, prospects, strategy, and financial needs. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, assumptions, and other factors described in the section titled "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q. Moreover, we operate in a highly competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q. While we believe that such information provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information, actual results, revised expectations, or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forwa

PERSONALIS, INC.

(1) Includes related party accounts receivable of $ 4.2 million and $ 2.5 million as of September 30, 2026 and December 31, 2025 , respectively.

(2) Includes related party liabilities of $ 5.0 million and $ 5.7 million as of September 30, 2026 and December 31, 2025 , respectively.

See Notes to the Consolidated Financial Statements.

PERSONALIS, INC.

(1) Includes related party revenue of $ 5.9 million and $ 1.1 million for the three months ended September 30, 2026 and 2025, respectively, and $ 17.4 million and $ 3.5 million for the nine months ended September 30, 2026 and 2025 , respectively.⁵

(2) Includes related party sales and marketing expenses of $ 4.8 million and $ 1.2 million for the three months ended September 30, 2026 and 2025, respectively, and $ 11.5 million and $ 2.7 million for the nine months ended September 30, 2026 and 2025 , respectively.

See Notes to the Consolidated Financial Statements.

PERSONALIS, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)

(In thousands)

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Net loss

$

( 33,801

)

$

( 21,652

)

$

( 95,516

)

$

( 57,458

)

Other compr